Dr. Reddy's Laboratories Ltd Stock Price, News & Analysis (NYSE:RDY)

$35.91 0.24 (0.67 %)
(As of 11/18/2017 01:47 AM ET)
Previous Close$35.91
Today's Range$36.12 - $35.66
52-Week Range$29.83 - $47.75
Volume162,634 shs
Average Volume309,798 shs
Market Capitalization$5.85 billion
P/E Ratio34.45
Dividend Yield0.82%
Beta0.41

About Dr. Reddy's Laboratories Ltd (NYSE:RDY)

Dr. ReddyDr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NYSE:RDY
  • CUSIP: N/A
  • Web: www.drreddys.com
Debt:
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 1.46%
  • Quick Ratio: 1.08%
Price-To-Earnings:
  • Trailing P/E Ratio: 34.45
  • Forward P/E Ratio: 31.50
  • P/E Growth: 10.37
Sales & Book Value:
  • Annual Sales: $2.171 billion
  • Price / Sales: 2.74
  • Cash Flow: $2.20 per share
  • Price / Cash: 16.33
  • Book Value: $11.25 per share
  • Price / Book: 3.19
Dividend:
  • Annual Dividend: $0.29
  • Dividend Yield: 0.8%
Profitability:
  • Trailing EPS: $1.04
  • Net Income: $186 million
  • Net Margins: 7.91%
  • Return on Equity: 9.10%
  • Return on Assets: 5.03%
Misc:
  • Employees: 22,175
  • Outstanding Shares: 165,820,000
 

Frequently Asked Questions for Dr. Reddy's Laboratories Ltd (NYSE:RDY)

What is Dr. Reddy's Laboratories Ltd's stock symbol?

Dr. Reddy's Laboratories Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How often does Dr. Reddy's Laboratories Ltd pay dividends? What is the dividend yield for Dr. Reddy's Laboratories Ltd?

Dr. Reddy's Laboratories Ltd announced a None dividend on Friday, August 4th. Investors of record on Monday, July 17th will be given a dividend of $0.294 per share on Thursday, August 10th. The ex-dividend date is Thursday, July 13th. View Dr. Reddy's Laboratories Ltd's Dividend History.

How were Dr. Reddy's Laboratories Ltd's earnings last quarter?

Dr. Reddy's Laboratories Ltd (NYSE:RDY) announced its earnings results on Tuesday, July, 26th. The company reported $0.00 earnings per share for the quarter. The business earned $479 million during the quarter, compared to the consensus estimate of $557 million. Dr. Reddy's Laboratories Ltd had a net margin of 7.91% and a return on equity of 9.10%. View Dr. Reddy's Laboratories Ltd's Earnings History.

When will Dr. Reddy's Laboratories Ltd make its next earnings announcement?

Dr. Reddy's Laboratories Ltd is scheduled to release their next quarterly earnings announcement on Friday, February, 2nd 2018. View Earnings Estimates for Dr. Reddy's Laboratories Ltd.

Where is Dr. Reddy's Laboratories Ltd's stock going? Where will Dr. Reddy's Laboratories Ltd's stock price be in 2017?

4 equities research analysts have issued 1-year price targets for Dr. Reddy's Laboratories Ltd's shares. Their predictions range from $30.51 to $30.51. On average, they expect Dr. Reddy's Laboratories Ltd's stock price to reach $30.51 in the next year. View Analyst Ratings for Dr. Reddy's Laboratories Ltd.

Who are some of Dr. Reddy's Laboratories Ltd's key competitors?

Who are Dr. Reddy's Laboratories Ltd's key executives?

Dr. Reddy's Laboratories Ltd's management team includes the folowing people:

  • Satish K. Reddy, Chairman of the Board (Age 49)
  • G. V. Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director (Age 56)
  • Saumen Chakraborty, President, Chief Financial Officer, Global Head - HR and IT & BPE (Age 55)
  • Sripada Chandrasekhar Ph.D., President, Global Head - Human Resources (Age 59)
  • Abhijit Mukherjee, Chief Operating Officer (Age 58)
  • Amit Biswas, Executive Vice President and Head - Integrated Product Development (Age 56)
  • Raghav Chari, Executive Vice President and Head - Proprietary Products (Age 46)
  • Samiran Das, Executive Vice President and Head - Global Manufacturing Operations (Age 57)
  • M. V. Ramana, Executive Vice President and Head-Branded Markets - India & Emerging Markets (Age 48)
  • Cartikeya Reddy, Executive Vice President and Head-Biologics (Age 46)

Who owns Dr. Reddy's Laboratories Ltd stock?

Dr. Reddy's Laboratories Ltd's stock is owned by a variety of of institutional and retail investors. Top institutional investors include DR. REDDYS HOLDINGS LTD (26.77%), Fisher Asset Management LLC (3.30%), Commonwealth Bank of Australia (1.27%), Dimensional Fund Advisors LP (0.35%), First Trust Advisors LP (0.25%) and JPMorgan Chase & Co. (0.18%). View Institutional Ownership Trends for Dr. Reddy's Laboratories Ltd.

Who sold Dr. Reddy's Laboratories Ltd stock? Who is selling Dr. Reddy's Laboratories Ltd stock?

Dr. Reddy's Laboratories Ltd's stock was sold by a variety of institutional investors in the last quarter, including Commonwealth Bank of Australia, Fisher Asset Management LLC, Prudential Financial Inc., Mitsubishi UFJ Trust & Banking Corp, Sei Investments Co., Flossbach Von Storch AG, Allianz Asset Management GmbH and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Dr. Reddy's Laboratories Ltd.

Who bought Dr. Reddy's Laboratories Ltd stock? Who is buying Dr. Reddy's Laboratories Ltd stock?

Dr. Reddy's Laboratories Ltd's stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, First Trust Advisors LP, JPMorgan Chase & Co., Sivik Global Healthcare LLC, Highbridge Capital Management LLC, Sectoral Asset Management Inc, Aperio Group LLC and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Dr. Reddy's Laboratories Ltd.

How do I buy Dr. Reddy's Laboratories Ltd stock?

Shares of Dr. Reddy's Laboratories Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dr. Reddy's Laboratories Ltd's stock price today?

One share of Dr. Reddy's Laboratories Ltd stock can currently be purchased for approximately $35.91.

How big of a company is Dr. Reddy's Laboratories Ltd?

Dr. Reddy's Laboratories Ltd has a market capitalization of $5.85 billion and generates $2.171 billion in revenue each year. The company earns $186 million in net income (profit) each year or $1.04 on an earnings per share basis. Dr. Reddy's Laboratories Ltd employs 22,175 workers across the globe.

How can I contact Dr. Reddy's Laboratories Ltd?

Dr. Reddy's Laboratories Ltd's mailing address is 8-2-337, Road No.3 Banjara Hills, HYDERABAD, 500-034, India. The company can be reached via phone at +91-40-49002900 or via email at [email protected]


MarketBeat Community Rating for Dr. Reddy's Laboratories Ltd (NYSE RDY)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Dr. Reddy's Laboratories Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Dr. Reddy's Laboratories Ltd (NYSE:RDY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $30.51 (15.04% downside)

Consensus Price Target History for Dr. Reddy's Laboratories Ltd (NYSE:RDY)

Price Target History for Dr. Reddy`s Laboratories Ltd (NYSE:RDY)

Analysts' Ratings History for Dr. Reddy's Laboratories Ltd (NYSE:RDY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017Jefferies Group LLCLower Price TargetUnderperform$31.62 -> $30.51N/AView Rating Details
9/21/2017Morgan StanleyUpgradeEqual Weight -> OverweightLowView Rating Details
8/31/2017CLSAUpgradeUnderperform -> OutperformHighView Rating Details
5/15/2017Deutsche Bank AGUpgradeSell -> HoldHighView Rating Details
7/26/2016Credit Suisse GroupDowngradeNeutral -> UnderperformN/AView Rating Details
5/2/2016The Goldman Sachs Group, Inc.Initiated CoverageNeutralN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Dr. Reddy's Laboratories Ltd (NYSE:RDY)

Earnings by Quarter for Dr. Reddy`s Laboratories Ltd (NYSE:RDY)

Earnings History by Quarter for Dr. Reddy's Laboratories Ltd (NYSE RDY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2018        
7/26/2016Q117$0.00$557.00 million$479.00 millionViewListenView Earnings Details
5/12/2016Q416$0.07$2.41 billion$567.00 billionViewListenView Earnings Details
2/9/2016Q316$0.51$2.48 million$599.00 millionViewN/AView Earnings Details
10/29/2015Q116$0.65$2.54 billion$609.00 millionViewListenView Earnings Details
5/12/2015Q415$0.49$559.00 million$621.00 millionViewListenView Earnings Details
1/29/2015Q315$0.53$561.00 million$610.00 millionViewN/AView Earnings Details
7/30/2014Q115$0.54$474.00 million$486.00 millionViewN/AView Earnings Details
5/13/2014Q414$0.52$0.47$557.00 million$580.00 millionViewN/AView Earnings Details
2/11/2014Q314$0.45$0.59$558.20 million$571.00 millionViewN/AView Earnings Details
10/31/2013Q214$0.46$0.65$561.00 million$537.00 millionViewN/AView Earnings Details
7/30/2013Q413$0.43$0.40$551.40 million$478.00 millionViewN/AView Earnings Details
5/14/2013$0.60ViewN/AView Earnings Details
2/14/2013Q313$0.40$505.00 million$522.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dr. Reddy's Laboratories Ltd (NYSE:RDY)
Current Year EPS Consensus Estimate: $1.14 EPS
Next Year EPS Consensus Estimate: $1.88 EPS

Dividends

Current Dividend Information for Dr. Reddy's Laboratories Ltd (NYSE:RDY)

Most Recent Dividend:8/10/2017
Annual Dividend:$0.29
Dividend Yield:0.81%
Dividend Growth:7.40% (3 Year Average)
Payout Ratio:27.88% (Trailing 12 Months of Earnings)
25.44% (Based on This Year's Estimates)
15.43% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Dr. Reddy`s Laboratories Ltd (NYSE:RDY)

Dividend History by Quarter for Dr. Reddy's Laboratories Ltd (NYSE RDY)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2017None$0.297/13/20177/17/20178/10/2017
6/6/2017$0.297/13/20177/17/20177/17/2017
6/6/2016Annual$0.287/14/20167/18/20167/18/2016
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Dr. Reddy's Laboratories Ltd (NYSE RDY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Dr. Reddy's Laboratories Ltd (NYSE RDY)

Source:
DateHeadline
Exclusive: Prescient messages about Indian companies circulate in WhatsApp groupsExclusive: Prescient messages about Indian companies circulate in WhatsApp groups
finance.yahoo.com - November 18 at 11:17 AM
Dr. Reddys Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from BrokeragesDr. Reddy's Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 17 at 1:48 AM
Dr. Reddys Laboratories Announces the Launch of Clofarabine Injection in the US Market - Business Wire (press release)Dr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the US Market - Business Wire (press release)
www.businesswire.com - November 14 at 3:23 PM
Dr. Reddys launches generic Clolar in U.S.Dr. Reddy's launches generic Clolar in U.S.
seekingalpha.com - November 14 at 7:16 AM
Dr. Reddys Launches Therapeutic Equivalent Generic Version Of Clolar InjectionDr. Reddy's Launches Therapeutic Equivalent Generic Version Of Clolar Injection
www.nasdaq.com - November 14 at 7:16 AM
Dr. Reddys Laboratories Announces the Launch of Clofarabine Injection in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the U.S. Market
finance.yahoo.com - November 14 at 7:16 AM
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down - NasdaqVIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down - Nasdaq
www.nasdaq.com - November 9 at 12:20 PM
Jefferies Group Weighs in on Dr. Reddys Laboratories Ltds FY2018 Earnings (RDY)Jefferies Group Weighs in on Dr. Reddy's Laboratories Ltd's FY2018 Earnings (RDY)
www.americanbankingnews.com - November 2 at 3:32 PM
Dr. Reddys Laboratories (RDY) Q2 2018 Results - Earnings Call Transcript - Seeking AlphaDr. Reddy's Laboratories' (RDY) Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 1 at 8:03 AM
Analyzing Neuralstem (CUR) and Dr. Reddys Laboratories (RDY)Analyzing Neuralstem (CUR) and Dr. Reddy's Laboratories (RDY)
www.americanbankingnews.com - October 31 at 9:16 PM
Dr. Reddys Q2 and H1 FY18 Financial Results - Business Wire (press release)Dr. Reddy's Q2 and H1 FY18 Financial Results - Business Wire (press release)
www.businesswire.com - October 31 at 8:30 AM
Dr. Reddy’s Q2 and H1 FY18 Financial ResultsDr. Reddy’s Q2 and H1 FY18 Financial Results
finance.yahoo.com - October 31 at 8:30 AM
Doctor Reddys posts 2Q profitDoctor Reddy's posts 2Q profit
finance.yahoo.com - October 31 at 8:30 AM
Dr. Reddys Laboratories Ltd. Sponsored ADR to Host Earnings CallDr. Reddy's Laboratories Ltd. Sponsored ADR to Host Earnings Call
finance.yahoo.com - October 31 at 8:30 AM
Analyzing Abbott Laboratories (ABT) & Dr. Reddys Laboratories (RDY)Analyzing Abbott Laboratories (ABT) & Dr. Reddy's Laboratories (RDY)
www.americanbankingnews.com - October 28 at 3:32 PM
FY2019 Earnings Estimate for Dr. Reddys Laboratories Ltd (RDY) Issued By Jefferies GroupFY2019 Earnings Estimate for Dr. Reddy's Laboratories Ltd (RDY) Issued By Jefferies Group
www.americanbankingnews.com - October 26 at 4:06 PM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddys Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - October 25 at 9:46 AM
DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the FirmDEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 25 at 9:46 AM
Dr. Reddys Laboratories Ltd (RDY) Set to Announce Earnings on TuesdayDr. Reddy's Laboratories Ltd (RDY) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 24 at 1:46 PM
Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela - MarketWatchImpax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela - MarketWatch
www.marketwatch.com - October 24 at 9:10 AM
DR. REDDYS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of ... - Business Wire (press release)DR. REDDY'S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of ... - Business Wire (press release)
www.businesswire.com - October 24 at 9:10 AM
RDY Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Dr. Reddy’s Laboratories, Ltd.RDY Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Dr. Reddy’s Laboratories, Ltd.
finance.yahoo.com - October 24 at 9:10 AM
RDY DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddys Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017RDY DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddy's Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - October 24 at 9:10 AM
DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Reminds Investors with Losses to Contact the FirmDEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 24 at 9:10 AM
DR. REDDY’S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit against Dr. Reddy’s Laboratories Ltd. – (RDY)DR. REDDY’S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit against Dr. Reddy’s Laboratories Ltd. – (RDY)
finance.yahoo.com - October 24 at 9:10 AM
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDYDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDY
finance.yahoo.com - October 24 at 9:10 AM
Dr. Reddys Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from BrokeragesDr. Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 23 at 2:06 AM
DR. REDDY’S 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action ...DR. REDDY’S 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action ...
www.businesswire.com - October 21 at 1:55 AM
5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Reminds Investors with Losses to Contact the Firm5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 21 at 1:55 AM
DR. REDDY’S 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Dr. Reddy’s Laboratories Ltd. – (RDY)DR. REDDY’S 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Dr. Reddy’s Laboratories Ltd. – (RDY)
finance.yahoo.com - October 21 at 1:55 AM
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Encourages Investors with Losses to Contact the FirmDEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 21 at 1:55 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddys Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDYSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy's Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDY
finance.yahoo.com - October 20 at 3:51 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddys Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - October 20 at 3:51 PM
The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Dr. Reddys Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Dr. Reddy's Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)
finance.yahoo.com - October 18 at 8:08 AM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddys Laboratories Ltd. (RDY) and Lead Plaintiff Deadline: October 24, 2017DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) and Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - October 18 at 8:08 AM
ONE WEEK DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Reminds Investors with Losses to Contact the FirmONE WEEK DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 18 at 8:08 AM
Dr. Reddys to Release Q2 FY18 Results on October 31, 2017Dr. Reddy's to Release Q2 FY18 Results on October 31, 2017
finance.yahoo.com - October 17 at 6:41 AM
RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddys Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddy's Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - October 17 at 6:41 AM
UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Encourages Investors with Losses to Contact the FirmUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 17 at 6:41 AM
UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the FirmUPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 14 at 7:14 AM
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Encourages Investors with Losses to Contact the FirmDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 13 at 8:35 AM
DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) To Contact The FirmDEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) To Contact The Firm
finance.yahoo.com - October 13 at 8:35 AM
DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Dr. Reddys Laboratories Ltd. (NYSE: RDY) To Contact The FirmDEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Dr. Reddy's Laboratories Ltd. (NYSE: RDY) To Contact The Firm
feeds.benzinga.com - October 13 at 6:50 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddys Laboratories Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDYSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy's Laboratories Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDY
finance.yahoo.com - October 12 at 8:50 AM
APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the FirmAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 12 at 8:50 AM
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr. Reddys Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr. Reddy's Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)
finance.yahoo.com - October 11 at 7:02 AM
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr. Reddys Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr. Reddy's Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)
finance.yahoo.com - October 11 at 7:02 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddys Laboratories Ltd. (RDY) and Lead Plaintiff Deadline: October 24, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) and Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - October 11 at 7:02 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddys Laboratories Ltd. (RDY) and Lead Plaintiff Deadline: October 24, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) and Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - October 11 at 7:02 AM
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Reminds Investors with Losses to Contact the FirmDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 11 at 7:02 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Dr. Reddy's Laboratories Ltd (NYSE RDY) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.